uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study of AMT-060 in hemophilia B patients will be presented at the World Federation of Hemophilia 2016 World Congress being held July 24-28, 2016 in Orlando, Florida.